ARTICLE | Clinical News
AP301: Phase IIa start
April 29, 2013 7:00 AM UTC
Next month, Apeptico will begin a placebo-controlled, Austrian Phase IIa trial to evaluate AP301 delivered via aerosol by nebulizer technology for up to 7 days in mechanically ventilated patients with...